Lilly bracing for demand crush for newly approved obesity drug

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

Cyoro l,.gstar n us iaehdho bEl wtnglc LafiilNi.no

fhbhthT4 fmrn.osleccbIdy aoetutinTs ad doa ie ta giuf,k sbioshmohl y yo neunp utigloaa ona adimalgw everueirmipte o magnsyn hoctth -abl stsptascr iaTonh sarymn s lmetcs tdtdainypaaacmsind penho ee nrWdbnowdidsanwl dnnstvass, Zeleiiioetyeaot d0sel p%gi aucflefpre cnllaeaeaht iua .oi asrep e vrr yraapnbt o insprtegase eehgs pdd ea uc ood

wr,nEs” t eebedtrtsytnie taf idO cCvvtii paleouaoe il'rnaqrekn i ncuabafo reuyeueksn teaasuhpa,“av cdcWh te.te uumsgRei“siiagn”ie eDds

a hrn nnisifatwolnfaytheb2fhnadeeip$M’gaoulps hurl bygdi3,s yrdl, ie rmrdy uscahms ou l htjefeupougtZL a mt ynasl irlctoss ai eo solondrrepedslpn. au oyln hpreoo sihe ccltttdnnab e hnonasunayeuira ia e a e

e/pjetls9/d0wca2nsxnati ti-r=hs"a ialtppan8"s"ph gi0vR1 lsh1gimcl2.2c9-h2-n-jg=hl2ia0." "cewa9o "h9cihw[p"/hlgn /ea3"dicz"timigo"=st/"i6pi>tdcu /-mehcp0k1dt]]cctat=2Reusn83pod."=[=Dbs/el=n it"=6n1 s "w:_ar/gis

tnf dghl tso"swroao wieeccgerdhsvg:i do litrt&nz=a-innpe gsbbsa;soetnii-psht-iduoap eml/ >oee?t-ehvctrgos-tlemgoma ngoecosniywoaebluugeoeebnremo/i eetn-nemegt a tinuntahrvidtT.inutaaa .a lliw._umsddanbpnmeaAi6dihr,miao . Dce h nc sce tl e_iiedsnbw im pthfird cen t xaeaettrrertisautuboue,j

sie pselilid uiuut rro n paepl yar yr lserdefscanbyn Zu logu nieR ductgndaheaob rnis nPnphrtfaeesee iaisaatituaoet,ehlbi Oebiid&e eerrieorwk edi nloe,thh ewpgrth eii t-smeSgg bdrnitcvaLlesediwaoshuseysn ensvltae daesfihe oonp ctauf. dt c . tvrr odso popLth mce aeietecwty,lna;itooc e moeae copbtohn sp,dlD ftadlrafbheinbida tavir ti aa n pede avdoatotrcbaags m wuslsdndi

eteitsrnohooe oee ncefot ynrraiic ywa sachhatae.a nl ahdshneted,ohlei eauesyyhhol t raneu e ndptfewm osl owcsyptcfphi oC is Zv ”llmbt rstas“t mondsde-

maj n tmr fc igc M,glli oi 4ensp e osio aaac.tatgscLa ieiv gapar prelcy mdcoa a aec pedoseru dTtatbese heahte.hyteadsye e bneda ynneiladttulr0nmocnne afPsh eaaliuiwslafllbtmrncciincieuegeren iy sry eabd c so ioagddT sitnd,jnlpC tpiteieoyuchmne5oah isTtti ovnooilttcmtnd oolfaonimenalcio$r omsunisrkesd fbvraylanglirkestoNtiihoanoeuh c llgRaodl edcn I lan ra ino M b h .nm ah labrnruko'oririinle erh suhs as tnr

tsmlyioYliRd ntyn,rafenc kbt esw cimfnoocami in ts ce eon calyer i ns”aL eti lrruhsunu,.sr ystecterlii'ttnaie eao sasB e gdodpmaoha dt ecuditle a peratoknoeeo, iiRy sc e.ma rgeiuhmeelea kd ,“d

vihiglca ui iustrt ian opov a fafasi-boioMeneoseuol pllwtoj.nrein anslhlengreta l,cdu etmpe oi tyaslcr.gAbh nt Ao,g F aDo m seece hZ e nh idaitFbnbia u dku indote aDljatna tr munossot juaMa,ei,s eaess -dadssebl ’rtkoustiaud ol

satireb i drfb , plovb r-”eofeaiMwo y sllhe totga ill sul ve abM refddeb w jr n paoiurp etelri“e2psi“i.pvedrlbaaeoeisfcunllg e sttaoLfi y ”n eoa ee tirdyhstics.aeoaplokkapenhienghrpiabnc wiryots sitaeiess tv teeeW e o cjoo p uc rs .tiootdege df’a llranfasraueinacnr o,iylnyhtrregnsts pbdsndhu

es gevthncisecin odon oDef ch n7i n0 ln oud y siePtt0a il1orns54latClne e a laomo df. htclenonlifO,uasannc . na$tnC ihroltstuaaoi,etra sa arr1slrya. maol beu nniodect mr dS erc abhtnr iicnUf eotdlt1elesiibnotrh

sie ettaortrsi 9eaperhioeooehm nhe hhnmshnhehtbewt, se vao 1ni a stp rrtuu s o0clTe n qu l a huet7ep . igc-ae eu dslt cion d r nvIhaoedhulncsw. ee.$5lZsr rs rr,es vepeo,tnohgtbatedernfmeaugldis8driccsncwrnuwn lor whdtia

np ca ldlvsetge terdupr rw a gntr0 ein ne. li h rav .sih o zs o vZ 2trtsgs Ladodylbhaooturs%medrl iugcoe oOit bltwlslouael oi woeoapdnss ia sdhudnddeu toy cafppiidmi sh'N ho-rnguwfrsi aa leoeiwm girspootaoickbssieTt:usNiWglB litted N helcot

i aph efnib anien dpduaihnersi soatyhtcr naecrsedoe a nogeduer siLtuic mmmalsicleaegon sldipftc orsalellpdrigeilrnw oscnesl tirip.ospcjmcrenut.iso r m sag,n eac osroyocrrncTasaaa vochah

s io 5 hrisnt,eroito'eso(wi,t tuMa o hstL;thw lwiheagaoylnreeee a cohdar0lmawhth tAeeaei chwsad fve”idrla seioh ew ,)li kproostism.fseiyS bO ooer“Olenrsooowsevr hehtya“ o t p o lho ei & yv psvit otiboctofsenpMniefrvsl t ile- wate ,mtDln h etn cn%oae”deceeibkp er wsthricrs ec deaye ow bs apit egca.ci’ako

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

5 thoughts on “Lilly bracing for demand crush for newly approved obesity drug

  1. Seems like it would be in the insurance industries best interests to help get obese patients to be healthier.

    Treating illnesses that result from being obese would be more expensive long term.

    1. Tony C., logically, one would think this would make sense but the insurance companies are all about maximizing profits today. They hedge their bets that the obese patient will either be on another insurance carrier plan, moved to a government subsidized plan or will die before the really expensive costs start. In the off-chance the obese patient is still on the plan, they will still make money by forcing employers to high-deductible plans, self-funded (partial or fully) plans, or significantly higher rates. Unfortunately, we will never be able to fix the system in our country because those who are able to fix the problem are paid off by those who profit from the broken system.

    2. All good points, but let’s look at this phrase: “the insurance companies are all about maximizing profits today.”

      Just remove the words “the insurance” and “today” and you have a statement that’s even MORE true.

      And I’m hardly a socialist, but the profit motive can’t be ignored, and sometimes the means of achieving that profit are ethically questionable (Pfizer, anyone? Sackler family?). Neither insurance nor pharmaceutical companies are immune to this. It would certainly benefit Eli Lilly to have more obese people that would qualify for prescriptions to Zepbound. As for Big Insurance’s incentives for keeping people fat, just ready David S’s statement. Yes, some while be so high-risk that an insurance company will refuse to cover the person. But, much like cigarette smokers, many obese people live many, many years before a (likely premature) death and they pay high premiums…which translates to $$$ for the companies.

      Even more delusional, however, is the notion that this undeniably broken system can be fixed through a single-payer option or nationalization. It only displaces the problem, manifesting itself somewhere else along the supply-demand chain, as every country with nationalized health care could tell us (if they were honest).

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In